Hope through research
In the past twenty years, many advances have been made in our understanding of the human immunodeficiency virus (HIV) and effective antiretroviral therapies have been developed. While considerable advances have been made, new therapeutic options are necessary to overcome resistant viral strains or intolerance to existing drugs. Fuzeon® (enfuvirtide) is an antiretroviral peptide drug, derived from the heptad repeat 2 (HR2) domain of the GP41. This drug is the first of a new class of agents called HIV-1 fusion inhibitors that block the fusion of the viral particle with the host target cell, Fuzeon offers people infected with HIV renewed hope as a result of novel research developments.
Top of page